The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor

Summary

Epidemiological studies have shown a strong association between type 2 diabetes mellitus and cardiovascular diseases, and hypofibrinolysis may contribute to this phenomenon. The aim of this study was to determine the effect of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor (TAFI). Hyperglycaemia was mimicked in vitro by incubation of TAFI with glyceraldehyde and in vivo by hyperglycaemic clamping of healthy volunteers. The effects of long-term hyperglycaemia in vivo on TAFI were investigated by comparing TAFI from poorly regulated and tightly regulated patients with type 2 diabetes. In vitro glycated TAFI showed an altered migration pattern on SDS-PAGE due to aggregation. Glycated TAFI showed decreased activity after activation by thrombin-thrombomodulin in a glyceraldehyde-dosedependent manner and a reduced anti-fibrinolytic potential. In vivo, no differences in TAFI parameters were found after hyper-glycaemic clamping of healthy volunteers and between tightly and poorly regulated patients with type 2 diabetes. Moreover, TAFI purified from poorly regulated and tightly regulated patients with type 2 diabetes migrated similarly on SDS-PAGE, indicating little or no glycation of the protein. Despite the deleterious effects of glycation of TAFI in vitro on its function, TAFI was neither affected by hyperglycaemic clamping, nor by long-term hyperglycaemia in patients with type 2 diabetes. This is in contrast to fibrinolytic factors as plasminogen-activator inhibitor I and tissue-type plasminogen activator, which are affected. We therefore hypothesise that a normally functioning TAFI under hyperglycaemic conditions may tip the haemostatic balance towards hypofibrinolysis, which may contribute to the development of cardiovascular diseases in type 2 diabetic patients.

Keywords

TAFI - hyperglycaemia - diabetes mellitus - cardiovascular disease - protein glycation

• References

• 1 Haffner SM, Lehto S, Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
• 2 Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-172.
• 3 Sobel BE. Effects of glycemic control and other determinants on vascular disease in type 2 diabetes. Am J Med 2002; 113 (Suppl 6A): 12S-22S.
• 4 Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 2002; 32: 269-273.
• 5 Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in noninsulin-dependent diabetes mellitus. Ann Med 1996; 28: 371-380.
• 6 Fuller JH, Keen H, Jarrett RJ. et al. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 02: 964-966.
• 7 Kannel WB, D’Agostino RB, Wilson PW. et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672-676.
• 8 Meigs JB, Mittleman MA, Nathan DM. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. J Am Med Assoc 2000; 283: 221-228.
• 9 Sakkinen PA, Wahl P, Cushman M. et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.
• 10 Nilsson TK, Boman K, Bjerle P. et al. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med 1994; 235: 419-423.
• 11 Juhan-Vague I, Roul C, Alessi MC. et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373.
• 12 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462.
• 13 Hori Y, Gabazza EC, Yano Y. et al. insulin resistance is associated with iincreased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metabolism 2002; 87: 660-665.
• 14 Rigla M, Wagner AM, Borrell M. et al. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients. Metabolism 2006; 55: 1437-1442.
• 15 Eaton DL, Malloy BE, Tsai SP. et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
• 16 Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518.
• 17 Wang W, Boffa M, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181.
• 18 Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34.
• 19 Usui T, Shimohira K, Watanabe H. et al. Detection and determination of glyceraldehyde-derived advanced glycation end product. Biofactors 2004; 21: 391-394.
• 20 Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198-1206.
• 21 Dunn EJ, Philippou H, Ariens RA. et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071-1080.
• 22 Nieuwdorp M, van Haeften TW, Gouverneur MC. et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006; 55: 480-486.
• 23 Mosnier LO, Von dem Borne PA, Meijers JC. et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
• 24 Marx PF, Hackeng TM, Dawson PE. et al. Inactivation of activated thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-12415.
• 25 Pahlman LI, Marx PF, Morgelin M. et al. Thrombin-activatable fibrinolysis inhibitor binds to Streptococcus pyogenes by interacting with collagen-like proteins A and B. J Biol Chem 2007; 282: 24873-24881.
• 26 Willemse J, Leurs J, Verkerk R. et al. Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate. Anal Biochem 2005; 340: 106-112.
• 27 Schatteman KA, Goossens FJ, Scharpé SS. et al. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 807-813.
• 28 Rouser G, Fleisher S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 05: 494-496.
• 29 Brunner J, Skrabal P, Hauser H. Single bilayer vesicles prepared without sonication. Physico-chemical porperties. Biochim Biophys Acta 1976; 455: 322-331.
• 30 Curvers J, Thomassen MC, Nicolaes GA. et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94.
• 31 Bobbink IW, De Boer HC, Tekelenburg WL. et al. Effect of extracellular matrix glycation on endothelial cell adhesion and spreading: involvement of vitronectin. Diabetes 1997; 46: 87-93.
• 32 Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
• 33 Valnickova Z, Thogersen IB, Christensen S. et al. Activated human plasma carboxypeptidase B is retained in the blood by binding to α₂-macroglobulin and pregnancy zone protein. J Biol Chem 1996; 271: 12937-12943.